While the INDEPENDENCE trial focused on complete transfusion independence, a key takeaway is that less stringent but highly valuable patient outcomes are crucial. Achieving a 50% reduction in transfusion needs offers a significant quality-of-life improvement. This suggests future trials should incorporate more flexible, patient-centric secondary endpoints that reflect real-world clinical benefits.

Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

Interferon can take 6-8 months to achieve a complete hematologic response. To manage patients during this period and avoid frequent phlebotomies, clinicians can prescribe a short, overlapping course of faster-acting hydroxyurea, providing immediate control while transitioning to the long-term therapy.

The target platelet count for ITP patients should be tailored to their lifestyle, bleeding history, and quality of life goals. A normal platelet count is not necessary, and different thresholds are appropriate for different patients (e.g., someone planning a ski trip versus a sedentary individual).

Unlike in CML where treatment-free remission is an established goal, discontinuing interferon in PV after a deep molecular response is considered theoretical and experimental. Clinicians caution against setting this as an expectation for patients, as most will require indefinite therapy to maintain control.

Patients with ITP who fail or are intolerant to one TPO receptor agonist (e.g., eltrombopag) should not be considered a class failure. Switching to another TPO agent is a viable strategy that can induce a response in nearly half of these cases, particularly for intolerance.

While not standard of care, TPO receptor agonists like romiplostim can be used in the third trimester of pregnancy to raise platelet counts above 75,000 for epidural anesthesia. This is considered a reasonable option after critical fetal development is complete, avoiding the need for pre-pregnancy splenectomy.

Eltrombopag is a potent iron chelator that can cause or worsen iron deficiency. In ITP patients with existing iron deficiency, alternative TPO receptor agonists like avatrombopag or romiplostim, which do not chelate iron, should be used instead.

Some ITP patients with extremely low platelet counts don't bleed because their platelets are enormous. This is due to the principle of 'conservation of platelet mass.' Automated counters can undercount these large platelets, so the functional platelet count is higher than reported, reducing bleeding risk.